• Explore /
  • Poster
  • / Predicting resistance to first-line FOLFOX plus bevacizumab in metastatic colorectal cancer: Final results of the multicenter, international PERMAD trial.

Predicting resistance to first-line FOLFOX plus bevacizumab in metastatic colorectal cancer: Final results of the multicenter, international PERMAD trial.

Abstract Poster

Authors

null

Thomas Seufferlein

Department of Medicine I, Hospital of the University Ulm, Ulm, Germany

Thomas Seufferlein , Thomas Jens Ettrich , Alexander Stein , Dirk Arnold , Gerald W. Prager , Stefan Kasper , Michael Niedermeier , Lothar Müller , Stefan Kubicka , Alexander Koenig , Petra Büchner-Steudel , Kai Wille , Angelika M. R. Kestler , Andreas W. Berger , Lukas Perkhofer , Ludwig Lausser , Hans A. Kestler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Colorectal Cancer

Track

Colorectal Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

NCT02331927

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 115)

DOI

10.1200/JCO.2021.39.3_suppl.115

Abstract #

115

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Hans A. Kestler

First Author: Sunil Sharma

First Author: Yoshiyuki Yamamoto

First Author: Kathrin Heinrich